ClinicalTrials.Veeva

Menu

Precision-Medicine Diagnostic Support in Hospitalized Veterans With Acute Kidney Injury (PRECISE-AKI)

VA Office of Research and Development logo

VA Office of Research and Development

Status

Begins enrollment in a year or more

Conditions

Acute Kidney Injury (AKI)

Treatments

Other: PRECISE-AKI Clinical Decision Support Tool

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT07217808
HSR3-017-24W

Details and patient eligibility

About

Acute kidney injury (AKI) affects up to 20% of hospitalized Veterans and is strongly associated with morbidity and death. AKI is a diverse condition and timely and accurate diagnosis of the type of AKI is critical to begin appropriate therapies, especially those causes that require specific treatments beyond general supportive care. Yet, there are still significant gaps in the initial evaluation of AKI among hospitalized patients. Clinical decision support systems (CDSS) have shown promise to address these barriers, but most consist of simple alerting schemes and general care recommendations provided at a single point in time. The goal of this proposal is to develop and test the feasibility and usability of a rule-based and Artificial Intelligence-assisted precision CDSS tool (PRECISE-AKI) that can provide cognitive support to improve timely initial diagnostic evaluation of AKI.

Full description

Acute kidney injury (AKI), defined as a sudden loss of kidney function, affects up to 20% of hospitalized Veterans and is strongly associated with chronic kidney disease, poor quality of life, and death. Clinical practice guidelines recommend timely identification of the cause of AKI, but gaps remain in conducting the initial and subsequent diagnostic evaluation. Some causes of AKI also require specific treatments beyond supportive care, can be challenging to diagnose, and can require even more detailed evaluation including kidney biopsies. This clinical trial will evaluate the usability and feasibility of an Artificial Intelligence (AI)-assisted automated and comprehensive precision CDSS tool (PRECISE-AKI) to provide iterative cognitive support of general and nephrology-based providers in the diagnostic evaluation of hospitalized patients experiencing AKI within the Tennessee Valley Health Systems (TVHS). The investigators hypothesize that PRECISE-AKI will be acceptable, appropriate, and feasible to a variety of users and improve the diagnostic evaluation of hospitalized patients AKI.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Eligible providers will be those that have at least 4 weeks of inpatient ward team or consultation team activity during a 12-month period.
  • Case inclusion criteria will consist of hospitalizations that meet criteria for Kidney Disease Improving Global Outcomes Stage 2 injury or persistent Stage 1 injury seen by eligible providers.

Exclusion criteria

  • Ineligible providers will be those that have < 4 weeks of inpatient ward team of consultative team activity during a 12 month period.
  • Hospitalizations with non-persistent (<48 hours) stage 1 injury or less.

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

60 participants in 2 patient groups

Control (Usual Care)
No Intervention group
Description:
The Control arm will consist of usual care with no additional clinical decision support tool guidance
PRECISION AKI Clinical Decision Support
Experimental group
Description:
The Intervention arm will consist of Clinical Decision Diagnostic Support (CDS) provided by the PRECISE-AKI tool
Treatment:
Other: PRECISE-AKI Clinical Decision Support Tool

Trial contacts and locations

1

Loading...

Central trial contact

Michael E Matheny, MD MS MPH; Edward D Siew, MD MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems